Cited by 70Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Open access
Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K. +10 more·2020·Infection

Abstract

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s15010-020-01475-8

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The clinical utility of caspofungin is increasingly compromised by emergence of non-susceptible strains.

    “However, the clinical utility of caspofungin is increasingly compromised by the emergence of non‐susceptible strains [5, 6].”
  • The distribution of these carbohydrate molecules across dynamically distinct phases, as demonstrated in the SC5314 strain, was consistently observed in the spectra of other C. albicans strains, including JKC1450, JCK1583, JKC302, as well as BS1 strains.

    “It should be noted that distribution of these carbohydrate molecules across dynamically distinct phases, as demonstrated in the SC5314 strain, was consistently observed in the spectra of other C. albicans strains, including JKC1450, JCK1583, JKC302, as well as BS1 strains (Supplementary Fig. 1)66.”

    From Distinct echinocandin responses of Candida albicans and Candida auris cell walls revealed by solid-state NMR (2025) · cites this paper as [66]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [11]Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts (4th ed.), CLSI, Wayne, PA (M27-Ed4). 2017.

Cited by

Sorted by citations

Authors
Coste, A. T., Kritikos, A., Li, J., Khanna, N., Goldenberger, D., Garzoni, C., Zehnder, C., Boggian, K., Neofytos, D., Riat, A., Bachmann, D., Sanglard, D., Lamoth, F., The Fungal Infection Network of Switzerland (FUNGINOS), Lamoth, F., Khanna, N., Boggian, K., & Sanglard, D.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Basel (CH)
  • Clinica Luganese Moncucco (CH)
  • University Hospital of Geneva (CH)
Venue
Infection
Published
2020-07-13
Volume
48
Issue
5
Pages
761-766
ISSN
  • 0300-8126 (ISSN-L)
  • 1439-0973
OpenAlex
W3043323594
Cited by
69
References
13
Citations by year
2026: 5 · 2025: 10 · 2024: 16 · 2023: 12 · 2022: 11 · 2021: 11 · 2020: 3
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • Infection (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • IRIS (submittedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
FUNGINOS
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
echinocandin resistance, Candida albicans, Candida glabrata, candidemia, antifungal resistance, persistent candidemia, mortality, Switzerland
MeSH terms
Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida albicans, Female, Humans, Male, Middle Aged, Switzerland, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review